Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1691 results
March 2023
-
Media ReleaseNovartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onsetChildren in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous…
-
Media ReleaseNovartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancerNew approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months…
-
Media ReleaseSandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicinesSandoz investment expected to be at least USD 400m – MOU signed today in Ljubljana at ceremony led by Slovenian Prime Minister and Sandoz CEONew project underpins Sandoz ambition to drive future…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General MeetingShareholders approve 26th consecutive dividend increase to CHF 3.20 (+3.2%) per share for 2022; representing a 4.0% yield1 and approximately 61% payout of free cash flowShareholders confirm Joerg…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaireLes actionnaires approuvent la 26e augmentation consécutive du dividende à CHF 3,20 (+3,2%) par action pour 2022 ; représentant un rendement de 4.0%1 et une distribution du free cash-flow d’environ…
-
Media ReleaseAktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gutDie Aktionärinnen und Aktionäre genehmigen die 26. Dividendenerhöhung in Folge auf CHF 3,20 (+3,2 %) pro Aktie für 2022; dies entspricht einer Rendite von 4.0 %1 und einer Ausschüttung von rund 61 %…
-
Pulse UpdateNovartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
February 2023
-
StatementNovartis unwavering in support one year on from the start of the war in Ukraine
-
Media ReleaseNovartis announces the appointment of the Chairman-Designate of Sandoz Board of DirectorsGilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz BoardMr Ghostine to begin role as Sandoz Chairman following the spin-…
-
StatementNovartis releases emergency funding of USD 1 million for people in Turkey and Syria, and launches employee donation and volunteering programs
-
StatementNovartis announces support for people affected by the earthquake in Turkey and Syria
-
Media ReleaseSandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDASubmission supported by comprehensive analytical and clinical data packageDenosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2Sandoz continues to…